Loading...
01/10 16:16
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Sanofi's earnings call reflects strong financial performance, particularly with 9.7% sales growth and successful new product launches like Dupixent and Beyfortus. The company maintains a stable tax rate and is executing a significant share buyback program. While there are concerns about R&D expenses and margin growth, the optimistic guidance for Dupixent and new pipeline developments in immunology are positive indicators. The Q&A section reveals confidence in new acquisitions and market strategies, despite some uncertainties in regulatory outcomes and pricing pressures. Overall, the sentiment leans positive with potential stock price growth.
Net Sales Net sales increased by 10.1% at constant exchange rate in Q2. This growth was primarily driven by Immunology, by our pharma launches and by Beyfortus.
Gross Margin Gross margin improved by 1.5 percentage points, largely led by an improved product mix and efficiencies.
R&D Expenses R&D expenses increased by 17.7% due to the lower base of comparison last year with the onetime reimbursement from Sobi. Underlying R&D expenses, excluding this reimbursement, increased by around 7%.
Business EPS Business EPS was EUR 1.59, up 8.3%, reflecting our strong sales performance and improved gross margin.
Dupixent Sales Dupixent sales reached EUR 3.8 billion, up 21% in Q2, driven by the continued strong demand and improved indications across geographies. Momentum has been driven by the market growth across all indications where biopenetration remains low as well as by recent launches, including COPD.
U.S. Dupixent Sales In the U.S., sales reached EUR 2.8 billion, up 22.7% as Dupixent continues to lead in both new-to-brand prescriptions and total prescriptions across all established indications.
Outside U.S. Dupixent Sales Outside the U.S., sales again exceeded the EUR 1 billion mark, driven by volume growth in key markets.
Vaccine Business Sales Our vaccine business delivered solid growth in Q2, with sales increasing by 10.3%, driven by the Beyfortus expansion and benefiting from the effect of a late 2024-2025 flu season in the Northern Hemisphere.
Ayvakit Sales Ayvakit reached USD 175 million in sales in Q2. While this performance is not included in the Sanofi Q2 financials, it underscores both the high unmet need and Ayvakit's potential as the first approved medicine in advanced and indolent systemic mastocytosis.
ALTUVIIIO: Extended its strong performance, increasing market share through patient switches.
Beyfortus: Expanded presence in Southern Hemisphere countries, though these are smaller markets compared to Northern Hemisphere.
Qfitlia: Following FDA approval at the end of Q1, recorded initial sales with expected uptake.
Dupixent: Sales reached EUR 3.8 billion, up 21% in Q2, driven by strong demand and improved indications across geographies. Recent launches include COPD and CSU.
Ayvakit: Achieved USD 175 million in sales in Q2, marking strong performance in systemic mastocytosis.
Vaccines: Solid growth in Q2 with sales increasing by 10.3%, driven by Beyfortus expansion and late flu season in Northern Hemisphere.
Vicebio acquisition: Entered agreement to acquire Vicebio, enhancing vaccine development for respiratory pathogens.
Gross margin: Improved by 1.5 percentage points due to better product mix and efficiencies.
R&D expenses: Increased by 17.7%, reflecting investments in pipeline and acquisitions.
Capital redeployment: Executed acquisitions of Dren Bio, Vigil Neuroscience, Blueprint, and Vicebio, aligning with strategic priorities.
Sustainability: Ranked as the world's 10th most sustainable company by TIME, with eco-design principles for medicines and vaccines.
Pipeline expansion: Acquired assets like Ayvakit and VG-3927, focusing on rare diseases and immunology.
Market Conditions: Potential U.S. tariffs on EU exports could create uncertainties and negatively impact financial performance.
Competitive Pressures: Flu vaccine sales are expected to decrease by a mid-teens percentage due to competitive forces, particularly in the U.S. and Germany.
Regulatory Hurdles: Regulatory decisions are pending for several key drugs, including rilzabrutinib for ITP and other rare diseases, which could impact timelines and market entry.
Supply Chain and Operational Risks: Seasonality of flu and RSV vaccines creates uneven revenue distribution, with a larger portion of sales expected in the second half of the year.
Economic Uncertainties: Foreign exchange impact is estimated to negatively affect sales by 4% and EPS by 6% for the full year 2025.
Strategic Execution Risks: The integration of recent acquisitions like Blueprint Medicines and Vicebio poses challenges in aligning operations and achieving expected financial returns.
2025 Sales Growth: Sanofi has refined its 2025 sales guidance to high single-digit percentage sales growth at constant exchange rates, driven by strong performance in new launches, vaccines, and Dupixent.
Dupixent Sales Projections: Sanofi aims to achieve approximately EUR 22 billion in Dupixent sales by 2030, supported by market growth, expanded indications, and recent launches.
Vaccine Business Outlook: Sanofi anticipates modest growth for Beyfortus in 2025 and expects flu vaccine sales to decrease by a mid-teens percentage due to competitive forces. The sales split is projected to be 75% in Q3 and 25% in Q4.
R&D Expenses: Sanofi expects a moderate increase in R&D expenses in H2 2025, with a focus on supporting growth and future launches.
EPS Guidance: Sanofi confirms its EPS guidance of low double-digit percentage growth at constant exchange rates for 2025, absorbing additional costs from newly acquired businesses.
Regeneron Development Balance Impact: Sanofi projects a negative year-on-year BOI impact of approximately EUR 300 million in 2026 and EUR 800 million in 2027 due to the reimbursement arrangement with Regeneron.
Amvuttra Royalties: Sanofi expects significant royalty revenue from Amvuttra, contributing to its financial outlook until the end of the decade.
Pipeline Developments: Sanofi plans to advance its pipeline with new acquisitions and regulatory submissions, including rilzabrutinib for ITP and other rare diseases, and efdoralprin alfa for alpha-1 antitrypsin deficiency.
Share Buyback Program: We are executing our EUR 5 billion share buyback program in 2025, with over 80% already completed as of today. We remain firmly committed to completing the full program by the end of this year.
Sanofi's earnings call reflects strong financial performance, particularly with 9.7% sales growth and successful new product launches like Dupixent and Beyfortus. The company maintains a stable tax rate and is executing a significant share buyback program. While there are concerns about R&D expenses and margin growth, the optimistic guidance for Dupixent and new pipeline developments in immunology are positive indicators. The Q&A section reveals confidence in new acquisitions and market strategies, despite some uncertainties in regulatory outcomes and pricing pressures. Overall, the sentiment leans positive with potential stock price growth.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
